Harvey Capital Management Inc. Acquires 232,180 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Harvey Capital Management Inc. grew its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 86.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 499,570 shares of the company's stock after purchasing an additional 232,180 shares during the quarter. Harvey Capital Management Inc. owned about 0.51% of Aquestive Therapeutics worth $1,449,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in AQST. Deutsche Bank AG increased its holdings in shares of Aquestive Therapeutics by 63.9% in the fourth quarter. Deutsche Bank AG now owns 61,989 shares of the company's stock worth $221,000 after acquiring an additional 24,170 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Aquestive Therapeutics during the 4th quarter valued at about $498,000. Two Sigma Investments LP lifted its holdings in shares of Aquestive Therapeutics by 31.5% during the 4th quarter. Two Sigma Investments LP now owns 175,952 shares of the company's stock valued at $626,000 after purchasing an additional 42,160 shares in the last quarter. ProShare Advisors LLC lifted its holdings in shares of Aquestive Therapeutics by 79.8% during the 4th quarter. ProShare Advisors LLC now owns 25,232 shares of the company's stock valued at $90,000 after purchasing an additional 11,200 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Aquestive Therapeutics by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company's stock valued at $15,474,000 after purchasing an additional 82,958 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company's stock.

Aquestive Therapeutics Trading Down 0.5%

Shares of Aquestive Therapeutics stock traded down $0.02 on Friday, reaching $4.01. 1,146,536 shares of the company were exchanged, compared to its average volume of 1,495,973. Aquestive Therapeutics, Inc. has a one year low of $2.12 and a one year high of $5.80. The company has a market capitalization of $398.31 million, a price-to-earnings ratio of -6.80 and a beta of 1.97. The company has a 50-day moving average of $3.10 and a 200 day moving average of $3.01.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The firm had revenue of $8.72 million during the quarter, compared to the consensus estimate of $12.23 million. Analysts predict that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on AQST shares. Oppenheimer started coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They set an "outperform" rating and a $7.00 price objective on the stock. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, June 17th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Aquestive Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $10.14.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.